Antiviral strategies in equines
Résumé
Background: Viral diseases have an economic and medical impact on equine health. The main strategies in their control are based on prevention through vaccination and/or supportive treatments. To date, there are very few antiviral molecules in the equine therapeutic arsenal, apart from valacyclovir for EHV-1.
Objectives: In order to repurpose approved drugs, FDA-approved therapeutic libraries were tested on equine cells. Two molecules have shown promising antiviral activity: CLABEO and GANSES (anonymised molecules). The safety of these molecules in horses, including the tolerance, the pharmacokinetics and pharmacotoxicity, was
assessed.
Study design: In vivo experiments.
Conclusions: These results showed that the molecules are well tolerated by horses. Further studies are needed to test the antiviral spectrum of GANSES and CLABEO against equine pathogens as respiratory viruses or arthropod- borne equine encephalitis viruses.
Ethical animal research: Approved by the CENOMEXA No54 ethics committee (No APAFIS #30663-202103251639113_v6) and the Ministry of Higher Education, Research and Innovation.
Informed consent: Not applicable.
Competing interests: None declared.
Funding: The IFCE (Institut Français du Cheval et de l'Equitation) grant number Rech-CS-2020-010-SAVE_SATELLITE.